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Adrenal insuﬃciency and liver disease – Re-searchIt is always a debatable point whether there is much
diﬀerence between a paper rejected for publication ver-
sus the one published but rarely cited.
In a recent review on ‘‘Adrenal insuﬃciency and Liver
disease – what is the evidence?” [1] a relevant paper on the
topic [2] was ignored by the reviewerswho claimonly 5pa-
pers have been published on the topic in the literature.
Some 16 years ago, following clinical suspicion of func-
tional adrenal insuﬃciency in occasional patients with
end-stage cirrhosis, we embarked on a systematic study
of adrenal function in 51 consecutive adult patients with
end-stage non-alcoholic cirrhosis undergoing liver trans-
plant work-up. The study was restricted to those having
non-alcoholic liver disease in order to avoid the con-
founding eﬀects of alcohol on adrenocortical function.
Results were compared to 40 healthy controls. Compared
with healthy controls, patients had a 64% reduction in
maximal increments of plasma cortisol to indirect adrenal
stimulation via insulin-induced hypoglycaemia and a 39%
reduction to direct adrenal stimulation by ACTH (all
P < 0.001). There was a signiﬁcant negative correlation
between the severity of the underlying liver disease as as-
sessed by Child-Pugh scores and peak control response to
ACTH (r = 0.647,P < 0.0001) and insulin-induced hypo-
glycaemia (r = 0.597, P < 0.0001). Baseline morning
cortisol, free cortisol and dehydroepiandrosterone sulfate
levels were unchanged compared with healthy controls.
We concluded that hypothalamic–pituitary regulation
of adrenal function was signiﬁcantly blunted in end-stage
non-alcoholic liver disease.We postulated that functional
adrenal insuﬃciency might contribute to the mortality ofpatients with end-stage liver disease and raised the ques-
tion of the need for controlled studies of adrenocortical
replacement therapy during acute deteriorations (sepsis
and haemorrhage) in severe hepatic disease. Thus, it
would not seem unreasonable for future authors who
tackle this subject to reference this publication. I also feel
that the authors should have also have referenced even
older studies going back as far as 1957 that seem some-
what relevant to the topic. (These studies are referenced
in our paper.) The term ‘‘re-search” is sometimes most
apt.
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We thank Professor McCaughan for his interest in
our review and his comments regarding the incidence
of adrenal dysfunction in cirrhosis. We apologise for
not citing his paper but we chose to focus on studies
of adrenal insuﬃciency in the setting of critical illness,as it is in this particular context that data pertaining
to adrenal insuﬃciency may lead to corticotherapy being
applied to patients with liver disease.
In our review we highlight the fact that although adre-
nal insuﬃciency is common in critically ill patients with
liver disease andmay be associatedwith aworse outcome,
Letters to the Editor / Journal of Hepatology 48 (2008) 1018–1021 1019there are currently no randomised controlled trials that
show corticotherapy to be beneﬁcial in this patient group
[1]. In fact, aswe discussed in the article the haemodynam-
ic response to steroids may be independent of the degree
of adrenal insuﬃciency and therefore may represent a
purely pharmacological eﬀect. This is supported by the re-
cent data from the CORTICUS study group which
showed that patients with septic shock treated with corti-
costeroids have faster resolution of shock which is inde-
pendent of the response to adrenal stimulation but also
have an increased incidence of superinfection and new
septic shock [2]. Similar to the report by McCaughan
et al. we have also found a high incidence (53%) of adrenal
insuﬃciency in cirrhotic patients [3,4]. It is therefore un-
clear whether the adrenal insuﬃciency observed in criti-
cally ill liver patients is a pre-existing condition or
related to the critical illness per se. Given that there ap-
pears to be potential for adverse outcome with corticoste-
roid therapy we agree with Professor McCaughan that
controlled clinical trials examining the role of corticoste-
roid supplementation in cirrhotic patients with critical ill-
ness and adrenal insuﬃciency are urgently needed.References
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countries: Do we neglect a signiﬁcant problem in medical care?To the Editor:
It is with great interest that we read the article by the
Spanish Acute HCV study group identifying hospital
admission as a signiﬁcant risk factor for acquiring HCV
infection in Spain [1].While it iswell known that the trans-
mission of HCV may occur through medical procedures
in countries with a low or medium human development
index [2], infectionwithHCVduring inpatient or ambula-
tory treatment is thought to be uncommon in the devel-
oped countries. This is supported by the fact that HCV
is by far less infectious than HBV. Moreover, we have re-
cently reported that the risk of acquiring HCV by a nee-
dlestick injury is an extremely rare event and that the
risk of acute HCV infection after injury with an HCV-
contaminated needle in Europe is below 0.5% [3].
At ﬁrst view, these data are in contrast to the rather
high proportion of nosocomial HCV acquisition of 67%
reported by the Spanish Acute HCV study group.
Although this high proportion might be partially ex-
plained by the fact that patients were referred for antiviral
treatment, the data are in line with other reports from
Italy [4], France [5], and the USA [6]. We have analyzed
the data of the German National Acute HCV studies I
[7] and II [8] and the currently ongoing acute HCV-IIIstudy for the possible sources of HCV infection. We also
included the data of 31 patients who did not fulﬁl the
inclusion criteria for therapy in the Hep-Net Acute-
HCV-III study. Overall, the Hep-Net cohort consists of
254 patients with acute hepatitis C (November 15,
2007). Among those, hospital admission was a less impor-
tant risk factor as compared to the Spanish experience.
Only 38 (15%) of our acute hepatitis C patients reported
a medical procedure as the most likely risk factor for hav-
ing acquired HCV. The table lists the type of procedures
in these cases. The majority of those consisted of hospital
admissions for surgery (n = 30 cases). Other invasive pro-
cedures including dental treatment were present in only 4
cases. Medical procedures were signiﬁcantly more often
the probable cause of infection in patients older than 30
years of age (p = 0.002 vs. patients younger than 30 years)
but not associatedwith disease severity or time fromexpo-
sure to the onset of symptoms. Another, somewhat wor-
rying ﬁnding was that still more than 25% of patients
were not aware of any obvious source of infection (see Ta-
ble 1).
Although medical procedures as a risk factor for HCV
infection seem to be less important in Germany than in
Spain, our ﬁndings are still alarming. Screening for
